Serum lysosomal acid hydrolase activities in Graves' disease

Guillou, Hélène; David, Véronique; Lorcy, Yves; Treut, A. Le; Allannic, H; Gall, Jean‐Yves Le

doi:10.1016/0009-8981(82)90158-9

Cited by 6 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical importance of AFU is indicated by the occurrence, albeit rare, of a deficiency state that results in a neurovisceral storage disease known as fucosidosis (Durand et al, 1969), and by the observation that women with low serum activity of the enzyme may be prone to ovarian carcinoma (Lynch et al, 1985). Raised serum concentrations of AFU have been described in patients with a variety of benign diseases, including diabetes, hyperthyroidism, toxic oil syndrome and, of particular relevance to the present study, cirrhosis, alcoholic hepatitis and acute viral hepatitis (Reglero et al, 1980;Calvo et al, 1982;Guillou et al, 1982;Cabezas-Delamore et al, 1983;Deugnier et al, 1984;DiCioccio et al, 1985). Increased AFU activity has also been reported in association with carcinoma of the lung, breast, stomach, ovary and uterus and, more recently, with hepatocellular carcinoma (HCC) (Reglero et al, 1980;Calvo et al, 1982;Deugnier et al, 1984;DiCioccio et al, 1985).…”

mentioning

confidence: 60%

Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in southern African blacks

Bukofzer

Stass²,

Kew³

et al. 1989

Br J Cancer

View full text Add to dashboard Cite

Summary The purpose of this study was to compare alpha-L-fucosidase and alpha-fetoprotein as serum markers of hepatocellular carcinoma in 72 southern African blacks with this tumour and 64 matched patients with benign hepatic diseases which might be mistaken clinically for hepatocellular carcinoma. Alpha-Lfucosidase activity was assayed using p-nitrophenyl-L-fucopyranoside (pNpf) as a substrate and alphafetoprotein concentrations were measured by radioimmunoassay. Serum alpha-L-fucosidase activity in the patients with hepatocellular carcinoma (mean 1,268, s.e.m. + 83.7, median 1,150 and range 38-3,698 nmol pNpfml -h -1) was significantly higher than that in the matched controls (mean 798, s.e.m. +65.8, median 648 and range 273-3,825nmol pNpfml-l h-1) (P=0.0001). However, alpha-L-fucosidase was both less sensitive (75 versus 87%) and less specific (70 versus 87%) than alpha-fetoprotein as a serum marker of hepatocellular carcinoma. When, in an endeavour to eliminate false-positive results, the diagnostic cut-off level for alpha-L-fucosidase was increased to 1,500nmol pNpfml-' h-1 and for alpha-fetoprotein to 400ngml-1, the sensitivity of alpha-L-fucosidase fell to 21% whereas that of alpha-fetoprotein remained satisfactory at 78%. If the two markers were used together, the number of false-negative alpha-fetoprotein results was reduced from 13 to 5.5%. We conclude that alpha-L-fucosidase is less useful than alphafetoprotein as a single marker of hepatocellular carcinoma in southern African blacks. However, the two markers can profitably be used together.The lysosomal hydrolase, alpha-L-fucosidase (alpha-Lfucoside fucohydrolase; 3.2.1.51; AFU), is present in many mammalian tissues where it degrades fucose-containing glycoconjugates. A number of isomers of the enzyme have been identified in human tissues, including two hepatic forms (Robinson & Thorpe, 1973). The clinical importance of AFU is indicated by the occurrence, albeit rare, of a deficiency state that results in a neurovisceral storage disease known as fucosidosis (Durand et al., 1969), and by the observation that women with low serum activity of the enzyme may be prone to ovarian carcinoma (Lynch et al., 1985). Raised serum concentrations of AFU have been described in patients with a variety of benign diseases, including diabetes, hyperthyroidism, toxic oil syndrome and, of particular relevance to the present study, cirrhosis, alcoholic hepatitis and acute viral hepatitis (Reglero et al., 1980;Calvo et al., 1982;Guillou et al., 1982;Cabezas-Delamore et al., 1983;Deugnier et al., 1984;DiCioccio et al., 1985). Increased AFU activity has also been reported in association with carcinoma of the lung, breast, stomach, ovary and uterus and, more recently, with hepatocellular carcinoma (HCC) (Reglero et al., 1980;Calvo et al., 1982;Deugnier et al., 1984;DiCioccio et al., 1985). Deugnier and his colleagues (1984) found serum levels of AFU to be raised in European patients with HCC more often than serum concentrations of alpha-fetoprotein (AFP), although they cauti...

show abstract

mentioning

confidence: 60%

Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in southern African blacks

Bukofzer

Stass²,

Kew³

et al. 1989

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Lysosomal enzyme activity is dependent on the state of thyroid function. 46 47 The possible hypothetical mechanism was that thyroid hormones stimulated the biosynthesis of lysosomal enzymes, 48 whereas excessive thyroid hormones could lead to lysosomal enzyme leak because changes in lysosomal membrane permeability resulted from the increase in the production of reactive oxygen species. 49–51 Thyroid hormones might cause changes in uNAG levels by affecting kidney function and damaging kidney structure.…”

Section: Discussionmentioning

confidence: 99%

Variations of urinary N-acetyl-β-D-glucosaminidase levels and its performance in detecting acute kidney injury under different thyroid hormones levels: a prospectively recruited, observational study

Liang

Luo

Hu³

et al. 2022

BMJ Open

View full text Add to dashboard Cite

ObjectiveChanges in thyroid function will be accompanied by changes in urinary N-acetyl-β-D-glucosaminidase (uNAG) levels. Therefore, whether thyroid hormones interfere the ability of uNAG in detecting acute kidney injury (AKI) has raised concern in patients with critical illness.DesignA prospectively recruited, observational study was performed.SettingAdults admitted to the intensive care unit of a grade A tertiary hospital in China.ParticipantsA total of 1919 critically ill patients were enrolled in the study.Main outcome measuresTo investigate the variations of the ability of uNAG to detect AKI in patients with critical illness under different thyroid hormones levels (differences in area under the curve (AUC) for uNAG diagnosis and prediction of AKI with different thyroid hormones levels).ResultsThe bivariate correlation analysis revealed that FT3 and TT3 levels were independently associated with uNAG levels (p<0.001). FT3 and uNAG also showed correlation in multivariable linear regression analysis (p<0.001). After stratification according to the levels of FT3 or TT3, significant variation was observed in the uNAG levels with different quartiles (p<0.05). However, in patients with varying FT3 and TT3 levels, no significant difference was found in the AUCs of uNAG to detect AKI (p>0.05).ConclusionsEven if uNAG levels varied with FT3 and TT3 levels, these hormones did not interfere with uNAG’s ability to detect AKI in patients with critical illness.

show abstract

Hereditary fructose intolerance mimicking a biochemical phenotype of mucolipidosis: A review of the literature of secondary causes of lysosomal enzyme activity elevation in serum

Ferreira

Devaney

Hofherr

et al. 2016

American J of Med Genetics Pt A

View full text Add to dashboard Cite

We describe a patient with failure to thrive, hepatomegaly, liver dysfunction, and elevation of multiple plasma lysosomal enzyme activities mimicking mucolipidosis II or III, in whom a diagnosis of hereditary fructose intolerance (HFI) was ultimately obtained. She presented before introduction of solid foods, given her consumption of a fructose-containing infant formula. We present the most extensive panel of lysosomal enzyme activities reported to date in a patient with HFI, and propose that multiple enzyme elevations in plasma, especially when in conjunction with a normal plasma α-mannosidase activity, should elicit a differential diagnosis of HFI. We also performed a review of the literature on the different etiologies of elevated lysosomal enzyme activities in serum or plasma. © 2016 Wiley Periodicals, Inc.

show abstract

Serum lysosomal acid hydrolase activities in Graves' disease

Cited by 6 publications

References 16 publications

Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in southern African blacks

Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in southern African blacks

Variations of urinary N-acetyl-β-D-glucosaminidase levels and its performance in detecting acute kidney injury under different thyroid hormones levels: a prospectively recruited, observational study

Hereditary fructose intolerance mimicking a biochemical phenotype of mucolipidosis: A review of the literature of secondary causes of lysosomal enzyme activity elevation in serum

Contact Info

Product

Resources

About